859850-98-9

Basic information

• Product Name: 1-METHYL-5-PHENYL-1H-PYRAZOLE-3-CARBONYL CHLORIDE
• Synonyms: 1-METHYL-5-PHENYL-1H-PYRAZOLE-3-CARBONYL CHLORIDE;1-Methyl-5-phenyl-1H-pyrazole-3-carbonyl chloride 95%;1-Methyl-5-phenyl-1H-pyrazole-3-carbonylchloride95%
• CAS NO: 859850-98-9
• Molecular Formula: C₁₁H₉ClN₂O
• Molecular Weight: 220.65
• Mol File: 859850-98-9.mol

Chemical Properties

• Melting Point: 80-81,5°C
• Boiling Point: 366.9 °C at 760 mmHg
• Flash Point: 175.7 °C
• Appearance: /
• Density: 1.26 g/cm³
• Vapor Pressure: 1.42E-05mmHg at 25°C
• Refractive Index: 1.611
• CAS DataBase Reference: 1-METHYL-5-PHENYL-1H-PYRAZOLE-3-CARBONYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-METHYL-5-PHENYL-1H-PYRAZOLE-3-CARBONYL CHLORIDE(859850-98-9)
• EPA Substance Registry System: 1-METHYL-5-PHENYL-1H-PYRAZOLE-3-CARBONYL CHLORIDE(859850-98-9)

Safety Data

• Hazard Codes: C
• Statements: 14-29-34
• Safety Statements: 8-22-26-30-36/37/39-45
• RIDADR: 3261
• Hazardous Substances Data: 859850-98-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-METHYL-5-PHENYL-1H-PYRAZOLE-3-CARBONYL CHLORIDE is used as an intermediate in the synthesis of various pharmaceuticals. Its reactivity allows for the creation of new compounds with potential therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical industry, 1-METHYL-5-PHENYL-1H-PYRAZOLE-3-CARBONYL CHLORIDE serves as a key intermediate in the production of agrochemicals, contributing to the development of new pesticides and other agricultural chemicals.
Used in Specialty Chemicals Production:
1-METHYL-5-PHENYL-1H-PYRAZOLE-3-CARBONYL CHLORIDE is utilized as a building block in the synthesis of specialty chemicals, which are used in various applications such as coatings, adhesives, and other industrial processes.
Organic Synthesis:
1-METHYL-5-PHENYL-1H-PYRAZOLE-3-CARBONYL CHLORIDE is used as a reagent in organic synthesis for the preparation of a wide range of organic compounds, taking advantage of its ability to participate in substitution reactions and form new chemical entities.

InChI:InChI=1/C11H9ClN2O/c1-14-10(7-9(13-14)11(12)15)8-5-3-2-4-6-8/h2-7H,1H3

Upstream product

• 10250-65-4 methyl 1-methyl-5-phenyl-1H-pyrazole-3-carboxylate 
• 10199-51-6 1-methyl-5-phenyl-1H-prazole-3-carboxylic acid ethyl ester 
• 10199-53-8 1-Methyl-5-phenyl-1H-pyrazole-3-carboxylic acid 

Relevant articles and documents

Design and Evaluation of Bispidine-Based SARS-CoV-2 Main Protease Inhibitors

For the first time, derivatives of 3,7-diazabicyclo[3.3.1]nonane (bispidine) were proposed as potential inhibitors of the SARS-CoV-2 main viral protease (3-chymotrypsin-like, 3CLpro). Based on the created pharmacophore model of the active site of the protease, a group of compounds were modeled and tested for activity against 3CLpro. The 3CLpro activity was measured using the fluorogenic substrate Dabcyl-VNSTLQSGLRK(FAM)MA; the efficiency of the proposed approach was confirmed by comparison with literature data for ebselen and disulfiram. The results of the experiments performed with bispidine compounds showed that 14 compounds exhibited activity in the concentration range 1-10 μM, and 3 samples exhibited submicromolar activity. The structure-activity relationship studies showed that the molecules containing a carbonyl group in the ninth position of the bicycle exhibited the maximum activity. Based on the experimental and theoretical results obtained, further directions for the development of this topic were proposed.

Diphenylurea derivatives for combating methicillin- and vancomycin-resistant Staphylococcus aureus

A new class of diphenylurea was identified as a novel antibacterial scaffold with an antibacterial spectrum that includes highly resistant staphylococcal isolates, namely methicillin- and vancomycin-resistant Staphylococcus aureus (MRSA & VRSA). Starting with a lead compound 3 that carries an aminoguanidine functionality from one side and a n-butyl moiety on the other ring, several analogues were prepared. Considering the pharmacokinetic parameters as a key factor in structural optimization, the structure-activity-relationships (SARs) at the lipophilic side chain were rigorously examined leading to the discovery of the cycloheptyloxyl analogue 21n as a potential drug-candidate. This compound has several notable advantages over vancomycin and linezolid including rapid killing kinetics against MRSA and the ability to target and reduce the burden of MRSA harboring inside immune cells (macrophages). Furthermore, the potent anti-MRSA activity of 21n was confirmed in?vivo using a Caenorhabditis elegans animal model. The present study provides a foundation for further development of diphenylurea compounds as potential therapeutic agents to address the burgeoning challenge of bacterial resistance to antibiotics.